Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab.
Toulis
K A
KA
Anastasilakis
A D
AD
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D000069448:Denosumab; D005260:Female; D006801:Humans; D009894:Opportunistic Infections / Q000139:chemically induced*; D010024:Osteoporosis / Q000188:drug therapy; D053245:RANK Ligand / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab